Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia.

Front Oncol · 2025 · PMC12665517 · PMID 41333219

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

The median OS was associated with a borderline significant improvement in the oxaliplatin group (29.9 months, 95% CI 25.68–34.13) than in the irinotecan group (23.0 months, 95% CI 17.83–28.17; HR = 0.75, 95% CI 0.57–0.99; p = 0.043) ( Figure 2A ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.